In his session at CROI 2019, Jay Gobler from Merck & Co presented the preliminary data from his phase 2 clinical trial of MK-8591 for the treatment of HIV-1 infection.
By analyzing the association between baseline 10-year cardiovascular risk scores and NPZ-4, researchers determined whether 2 common CVD risk scores could predict later cognitive function. The findings were...
A new study presented at CROI 2019 explored whether switching to monthly long-acting CAB+RPV is noninferior to continuing current 3-drug oral ART in adults with virologically suppressed HIV-1 infection. ...
Alveolar macrophages play an important role in host defense against pathogenic microorganisms and tissue remodeling. In their study, Dr Charles P. Neff and colleagues investigated the effect of HIV and...
At CROI 2019, Dr Rosie Mngqibisa presented results from her study that evaluated whether concurrent use of rifampicin and efavirenz impacts the efficacy of DMPA, a commonly used contraceptive.
The relationship between COPD and myocardial infarction among individuals with HIV is not as well understood as in those without HIV. Researchers sought to define the relationship in individuals with HIV;...
New research presented at CROI 2019 compared the efficacy and safety of ART containing an integrase inhibitor with efavirenz (EFV) when initiated during pregnancy.
At CROI 2019, Dr Cindy Firnhaber presented results from her study that evaluated the efficacy of the HPV vaccine as adjuvant therapy among women with HIV and high-grade squamous intraepithelial lesion. ...
During her presentation at CROI 2019, Dr Constance A. Benson reviewed the steps that have been taken to improve the outlook of tuberculosis and what still needs to be done.
